Difluprednate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Difluprednate
Difluprednate.svg
Systematic (IUPAC) name
[(6S,8S,9R,10S,11S,13S,14S,17R)-17-(2-acetyloxyacetyl)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] butanoate
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a609025
Licence data US FDA:link
Legal status -only (US)
Routes topical dermatologic
Identifiers
CAS number 23674-86-4 YesY
ATC code D07AC19
PubChem CID 32037
DrugBank DB06781
ChemSpider 391990 N
UNII S8A06QG2QE N
KEGG D01266 YesY
ChEMBL CHEMBL1201749 N
Chemical data
Formula C27H34F2O7 
Mol. mass 508.551
 N (what is this?)  (verify)

Difluprednate is a corticosteroid, It is chemically a butyrate ester of 6(alpha),9(alpha)-difluoro prednisolone acetate. Accordingly, difluprednate is sometimes abbreviated DFBA, for difluoroprednisolone butyrate acetate.

Approval[edit]

On June 24, 2008, the US Food and Drug Administration (FDA) approved difluprednate for the treatment of post-operative ocular inflammation and pain.[1] It is marketed by Alcon under the tradename Durezol.

Clinical trials[edit]

Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a U.S. Phase 3 study evaluating difluprednate for the treatment of anterior uveitis.[2]

References[edit]